Investigators at Janssen Scientific Affairs LLC Report Findings in Schizophrenia (Racial Disparities In Utilization of First-generation Versus Second-generation Long-acting Injectable Antipsychotics In Medicaid Beneficiaries With Schizophrenia): Mental Health Diseases and Conditions – Schizophrenia

2023 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Pharma Business Daily -- Investigators discuss new findings in Mental Health Diseases and Conditions - Schizophrenia. According to news reporting originating from Titusville, New Jersey, by NewsRx correspondents, research stated, “Multiple studies report racial disparities in antipsychotic prescription patterns. This study assessed demographic and clinical factors associated with the utilization of first-generation (FG) versus second-generation (SG) long-acting injectable (LAI) antipsychotics.”

Financial support for this research came from Janssen Scientific Affairs, LLC.

Our news editors obtained a quote from the research from Janssen Scientific Affairs LLC, “This retrospective, observational cohort analysis used claims data from the IBM MarketScan ® Multi-State Medicaid database. The study included adults with an LAI claim between 01-January-2009 and 31-December-2018, an ICD-9-CM or ICD-10-CM diagnosis of schizophrenia, race recorded as Black or White, and >= 12 months of continuous enrollment before the index LAI. Descriptive analysis detailed the relationship between race and FG or SG LAI initiation. Multivariate logistic regression was used to assess potential associations with FG vs. SG LAI initiation, including clinical and demographic factors, comorbidities, and index year. A total of 10,773 patients were included: 6659 (62 %) Black and 4114 (38 %) White. Black patients had a higher utilization of FG LAIs than White patients (46.8 % vs. 38.9 %) over the 10 years analyzed. Black patients were more likely to utilize FG LAIs than White patients (odds ratio: 1.47; 95 % CI: 1.34, 1.62) after controlling for index year and covariates (race, age, gender, insurance plan type, Quan-Charlson Comorbidity index score, comorbidities, prior medications). Significant predictors of FG LAI utilization were older age, type of baseline oral antipsychotic (FG vs SG), type of coverage (managed care vs fee for service), and greater comorbidity burden. The utilization of FG LAIs was greater in Black compared to White Medicaid beneficiaries with schizophrenia over a 10-year period.”

According to the news editors, the research concluded: “These findings suggest that racial disparities exist in LAI initiation, with implications for differential quality of schizophrenia treatment.”

This research has been peer-reviewed.

For more information on this research see: Racial Disparities In Utilization of First-generation Versus Second-generation Long-acting Injectable Antipsychotics In Medicaid Beneficiaries With Schizophrenia. Schizophrenia Research, 2023;261:170-177. Schizophrenia Research can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Schizophrenia Research - http://www.journals.elsevier.com/schizophrenia-research/)

The news editors report that additional information may be obtained by contacting Jacqueline Pesa, Janssen Scientific Affairs LLC, Titusville, NJ, United States. Additional authors for this research include Zhiwen Liu, Alex Z. Fu, Alicia K. Campbell and Richard Grucza.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.schres.2023.09.033. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)